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Background: In stage IV colorectal cancer (CRC) with unresectable metastases, whether or not resection of the
primary tumor should be indicated remains controversial. We aim to determine the impact of primary tumor
resection on the survival of stage IV CRC patients with unresectable metastases.
Methods: We retrospectively investigated 103 CRC patients with stage IV colorectal cancer with metastases, treated
at Hiroshima University Hospital between 2007 and 2013. Of these, those who had resectable primary tumor but
unresectable metastases and received any chemotherapy were included in the study. We analyzed the overall
survival (OS) and short-term outcomes between the patients who received up-front systemic chemotherapy (USC
group) and those who received primary tumor resection followed by chemotherapy (PTR group).
Results: Of the 57 included patients, 15 underwent USC and 42 PTR. The median survival times were 13.4 and
23.9 months in the USC and PTR groups, respectively (P = 0.093), but multivariate analysis for the overall survival
showed no significant difference between the two groups (hazard ratio, 1.30; 95% confidence interval (CI), 0.60 to
2.73, P = 0.495). In the USC group, the disease control rate of primary tumor was observed in 12 patients (80.0%),
but emergency laparotomy was required for 1 patient. Morbidity in the PTR group was observed in 18 cases (42.9%).
Conclusions: The overall survival did not differ significantly between the USC and PTR groups. USC may help avoid
unnecessary resection and consequently the high morbidity rate associated with primary tumor resection for stage IV
CRC with unresectable metastases.
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Medical treatment of colorectal cancer (CRC) has sig-
nificantly improved over the past 10 years, mostly be-
cause of the introduction of combination chemotherapy
protocols, and, more recently, new biological agents [1].
The median survival time of CRC patients has recently
increased to over 2 years by using combinatorial therapy
with molecular targeted agents such as bevacizumab,
cetuximab, and panitumumab [2].* Correspondence: thinoi@hiroshima-u.ac.jp
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unless otherwise stated.However, in stage IV CRC with unresectable metasta-
ses, whether or not resection of the primary tumor
should be indicated remains controversial. Although it
has been previously demonstrated that primary tumor
resection or palliative surgery against symptomatic pri-
mary tumors is valuable, opinions vary on the need for
resection of asymptomatic primary tumors [3,4]. The
need for prophylactic resection of asymptomatic primary
tumors to prevent emerging symptoms is debatable, and
it is difficult to predict the contribution of such proce-
dures to quality of life improvements, especially when
the estimated survival time is limited [5]. Moreover, it
should be considered that patients with advanced CRChis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mortality [6-9].
Recent advances in systemic chemotherapy may result
in initially unresectable metastases becoming resectable,
and consequently, resection of the primary tumor can be
reassessed as part of a multidisciplinary therapeutic
process, instead of palliative care alone [9-13]. Conversely,
others have reported that, during up-front systemic
chemotherapy, 57.1% to 97.1% patients did not require the
additional surgery for morbidity including obstruction,
perforation, bleedings, and so forth, [14-17] and that the
mean interval between diagnosis and start of chemother-
apy was 23.1 days [17]. As well as to avoid the unnecessary
resection of primary tumor sometimes associated with
surgical morbidity and mortality, up-front systemic
chemotherapy was thought to be useful for earlier ad-
ministration of chemotherapy for metastases that be-
come life-threatening in the future and subsequently
may contribute to prolong the survival outcomes.
Since the current literature does not offer confirmative
evidence on the issue, we herein aimed to determine
whether primary tumor resection followed by chemo-
therapy or up-front systemic chemotherapy provides a




We retrospectively investigated 103 patients with stage IV
CRC, who did not have symptomatic primary tumor re-
quiring emergency surgery and thus contraindicating up-
front systemic chemotherapy, treated at the Department
of Gastroenterological and Transplant Surgery, HiroshimaFigure 1 Inclusion criteria.University Hospital between April 2007 and December
2013. Of these, 13 patients with unresectable primary
tumors due to multiple organ invasion and 22 patients
with resectable or possibly resectable metastases were
excluded from the study. Furthermore, 6 patients who
were indicated for supportive care, and 5 patients with
malignancies other than colorectal adenocarcinoma, in-
cluding neuroendocrine carcinoma, appendiceal cysta-
denocarcinoma, squamous cell carcinoma of the anal
canal, and multiple cancers under treatment, were also
excluded, resulting in 57 patients with a resectable pri-
mary tumor but unresectable metastases being included
in this study (Figure 1). Decision making of each treat-
ment option was owing to the patients’ choice under
sufficient informed consent from main surgeons and/or
medical oncologists. Fifteen patients were treated with
up-front systemic chemotherapy (USC) as initial therapy
and 42 were treated with primary tumor resection (PTR)
followed by chemotherapy.
This study was performed with permission of the Ethics
Committee of the Hiroshima University.
Chemotherapy
During the study period, almost all anti-cancer drugs in-
dicated for CRC were available in Japan; 5-fluorouracil/
leucovorin, capecitabine, S-1, oxaliplatin, irinotecan, bevaci-
zumab, cetuximab (since August 2008), and panitumumab
(since April 2010) were all administered to the patients,
while regorafenib or trifluridine were not. As a general rule
of our institute, oxaliplatin-based doublet chemotherapy
(mFOLFOX6 or XELOX) with any molecular targeted
agent was selected as first-line chemotherapy, and subse-
quently irinotecan-based doublet chemotherapy (FOLFIRI)
Niitsu et al. World Journal of Surgical Oncology  (2015) 13:162 Page 3 of 8with any molecular targeted agent was selected as sec-
ond line, although chemotherapy regimens were finally
decided on an individual basis by the attending medical
oncologists. Bevacizumab was administered even when
a primary tumor was present in the USC group, and
administered at least 1 month after primary tumor re-














Primary tumor site Right colon
Left colon
Rectum







Lymph node metastasis Negative
Positive
Sum of the longest diameters of metastases (mm)
Number of metastases
Number of organs with metastasis
Peritoneal dissemination
Total lines of chemotherapy
Use or any molecular target agents
Bevacizumab
Cetuximab and/or panitumumab*
Use of oxaliplatine combination
Use irinotecan combination
Conversion
USC: up-front systemic chemotherapy group. PTR: primary tumor resection group. B
KRAS: Kirsten rat sarcoma viral oncogene. CEA: carcinoembryonic antigen. Variables
Fisher’s exact test (categorical, binary) or Chi-square test (categorical, more than three
the KRAS exon 2 wild-type tumor only.in delayed wound healing. Genotyping of Kirsten rat
sarcoma viral oncogene (KRAS) exon 2 was performed
for all cases from April 2010, when the Japanese Ministry
of Health and Welfare approved its reimbursement for pa-
tients with health insurance. Before approval, the KRAS
exon 2 was genotyped only when cetuximab or panitumu-
mab was considered; therefore, the KRAS status wasteristics
USC (N = 15) PTR (N = 42) P value
13.4 (11.3 to 23.2) 19.2 (12.4 to 28.9) 0.232
63 (48 to 65) 61.5 (54 to 70.5) 0.568
7 8 0.048
8 34




















61 (46 to 150) 75 (41.5 to 109) 0.697
17 (6 to 52) 11.5 (5.5 to 28) 0.309
2 (1 to 2) 2 (1 to 2) 0.899
2 (13.3%) 7 (16.7%) 1.00
2 (2 to 3) 2 (1 to 3) 1.00
13 (86.7%) 37 (88.1%) 1.00
12 (80.0%) 33 (78.6%) 1.00
6 (100%) 16 (66.7%) 0.155
14 (93.3%) 36 (85.7%) 0.66
12 (80.0%) 26 (61.9%) 0.339
1 (6.7%) 0 (0%) 0.263
MI: body mass index. ASA score: American Society of Anesthesiologists score.
were statistically analyzed by Wilcoxon’s rank-sum test (quantitative variables),
variables). *Use of cetuximab and/or panitumumab was presented as frequency in
Table 2 Surgical procedures offered to patients in the
PTR and USC groups
PTR (N = 42) USC (N = 6) P value
Surgical procedure, n
Ileocecal resection 5 - 0.181
Right hemicolectomy 4 -
Transverse colectomy 4 -
Left hemicolectomy 2 -
Sigmoidectomy 11 2
Hartmann operation 3 1
Abdominoperineal resection 5 -
High anterior resection 3 -
Low anterior resection 5 2




Open conversion, n 0 0 N.A.
USC: up-front systemic chemotherapy group. PTR: primary tumor resection group.
N.A.: not available. Variables were statistically analyzed by Fisher’s exact test
(categorical, binary) or Chi-square test (categorical, more than three variables).
Figure 2 Overall survival between the USC and PTR groups. Median
survival times were 13.4 and 23.9 months in USC and PTR, respectively,
and overall survival was not significantly different in the two groups.
USC: up-front systemic chemotherapy group. PTR: primary tumor
resection group. HR: hazard ratio. CI: confidence interval.
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were offered only when a wild-type KRAS exon 2 genotype
was confirmed. Other RAS genotypes were not studied.
Statistical analyses
The following baseline characteristics were compared
between the USC and PTR groups: age, sex, body mass
index (BMI), Eastern Cooperative Oncology Group per-
formance status (ECOG-PS) [18], American Society of
Anesthesiologists score (ASA score), tumor location
(colon or rectum), KRAS status, carcinoembryonic anti-
gen (CEA), invasion depth and lymph node metastases
classified according to the UICC-TNM stage (Union for
International Cancer Control 7th edition [19]), sum of
the longest diameters of the three largest metastases,
number of metastases, number of organs with metasta-
sis, and chemotherapy regimens (number of courses and
anti-cancer drugs used). The operative procedures were
also analyzed in both PTR and USC groups. Moreover,
postoperative morbidity, response rate, disease control
rate in both groups, and symptom occurrence rate after
initiation of USC by primary tumor progression were
studied. The results are reported as median and interquar-
tile range for quantitative variables and as frequencies for
categorical variables. Comparisons were conducted using
Wilcoxon’s rank-sum tests for quantitative variables and
Fisher’s exact tests or Pearson’s Chi-square tests for cat-
egorical variables.
Survival outcomes were analyzed as of September
2014 and were compared between the two groups using
log-rank tests and summarized as Kaplan-Meier curves
and hazards ratios (HRs) with 95% confidence intervals
(CIs). Subsequently, multivariate analyses for survival
were conducted using Cox proportional hazard models,
including variables at P < 0.1 in the log-rank tests. The
results of these univariate or multivariate analyses are
presented as the odds ratio (OR) or HR and 95% CI with
the corresponding P value.
All statistical analyses were performed using JMP 10
software (SAS Institute, Cary, NC, USA).
Results
On analyses of the baseline demographic and clinico-
pathological characteristics, sex and the primary tumor
sites were found to significantly differ between the two
groups, whereas other variables such as the age, BMI,
ECOG-PS, ASA score, CEA, KRAS status, depth of inva-
sion, lymph node metastasis, sum of the longest tumor
diameter, number of metastases, number of organs with
metastasis, peritoneal dissemination, and chemotherapy
regimens did not significantly differ (Table 1). There
were no differences with regard to the operative procedure
offered to patients in both groups (Table 2). The median
survival times were 13.4 months and 23.9 months for theUSC and PTR groups, respectively, as determined by using
the Kaplan-Meier analyses, and there was no statistical
significance in overall survival (OS) (Figure 2). Moreover,
the multivariate Cox regression analysis did not reveal any
significant differences in survival between the two treat-
ment options, whereas the KRAS status and number of
Table 3 Univariate and multivariate analysis on overall survival
Univariate analysis Multivariate analysis
Factor N HR (95% CI) P value HR (95% CI) P value
Treatment
PTR 42 Reference 0.093 Reference 0.495
USC 15 1.76 (0.87 to 3.35) 1.30 (0.60 to 2.73)
Age
<63 years 30 Reference 0.923 - -
≥63 years 27 0.97 (0.52 to 1.80)
Sex
Male 15 Reference 0.116 - -
Female 42 1.70 (0.84 to 3.24)
BMI
<22 kg/m2 33 Reference 0.627 - -
≥22 kg/m2 24 0.85 (0.44 to 1.61)
Tumor location
Colon 35 Reference 0.280 - -
Rectum 22 0.70 (0.35 to 1.32)
KRAS status
Wild type 30 Reference 0.001 Reference 0.004
Mutant or unknown 27 2.81 (1.49 to 5.31) 2.89 (1.41 to 6.02)
CEA
<5.1 10 Reference 0.822 - -
≥5.1 47 1.09 (0.53 to 2.56)
Invasion depth
T1-3 24 Reference 0.0540 Reference 0.065
T4a, T4b 33 1.93 (0.99 to 3.87) 1.97 (0.96 to 4.24)
Lymph node metastasis
Negative 6 Reference 0.225 - -
Positive 51 2.47 (0.89 to 10.2)
Sum of the longest diameters of metastases
<67 mm 29 Reference 0.184 - -
≥67 mm 28 1.52 (0.82 to 2.87)
Number of metastases
<13 29 Reference 0.084 Reference 0.199
≥13 28 1.72 (0.93 to 3.24) 1.55 (0.79 to 3.09)
Number of organs with metastasis
1 22 Reference 0.010 Reference 0.037
≥2 35 2.52 (1.26 to 5.48) 2.14 (1.04 to 4.76)
Peritoneal dissemination
No 48 Reference 0.129 - -
Yes 9 1.90 (0.76 to 4.16)
Total lines of chemotherapy
1 to 2 35 Reference 0.111 - -
≥3 22 0.60 (0.31 to 1.13)
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Table 3 Univariate and multivariate analysis on overall survival (Continued)
Use of anti-VEGF antibody
No 12 Reference 0.403 - -
Yes 45 0.71 (0.34 to 1.69)
Use of anti-EGFR antibody (KRAS wild
patient only)
No 8 Reference 0.197 - -
Yes 22 2.22 (0.73 to 9.59)
USC: up-front systemic chemotherapy group. PTR: primary tumor resection group. HR: hazard ratio. CI: confidence interval. BMI: body mass index. KRAS: Kirsten rat
sarcoma viral oncogene. EGFR: epidermal growth factor receptor. CEA: carcinoembryonic antigen. VEGF: vascular endothelial growth factor.
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pendent prognostic factor for the survival of patients with
CRC in the current study (Table 3).
The response rates to first-line chemotherapy were
33.3% and 42.9% in the USC and PTR groups, respect-
ively (P = 0.558), while the disease control rates were
80.0% and 71.4%, respectively (P = 0.735). In the USC
group, 3 patients (20.0%) experienced symptoms due to
primary tumor after initiation of chemotherapy, resulting
in additional surgery. For one of the three, emergency
laparotomy was required because of perforative periton-
itis caused by tumor necrosis after USC. On the other
hand, 3 patients received primary tumor resection, not
as palliation for symptoms caused by the primary tumors
but as a multidisciplinary therapy after the primary tu-
mors and metastases were controlled with up-front
chemotherapy. In total, 6 patients received the surgery,
and 3 patients (50%) experienced postoperative morbidity,
including 2 surgical site infections (SSI), 1 anastomotic
leakage, and 1 pneumonia.
In the PTR group, the morbidity was observed in 18
cases (42.9%), including 6 postoperative ileuses, 3 anas-
tomotic leakages, 3 surgical site infections, and 10 cases
with other complications such as liver function test ab-
normalities and delirium. Of these, 6 cases (14.3%) were
categorized as > grade 3 complications.
Discussion
In stage IV CRC with unresectable metastases, whether
primary tumor resection followed by chemotherapy or
up-front systemic chemotherapy provides a better prog-
nosis remains controversial. Contrary to our result that
the OS rates do not differ according to primary tumor
resection in stage IV CRC with unresectable metastases,
some previous reports have indicated a better survival
benefit with primary tumor resection. In a recent meta-
analysis of eight studies with available survival data,
primary tumor resection was associated with longer
OS, with an estimated median standardized difference
of 6.0 months [11]. In another meta-analysis of 21
studies, primary tumor resection also contributed to
longer OS; however, most of the studies included wereretrospective (18 of 21) and chemotherapy regimens
differed from each other. With regard to molecular
targeted agents, only two study included bevacizumab and
one cetuximab (with bevacizumab) [20]. Additionally, two
recent sub-analyses of data from randomized trials [12,13]
showed the survival benefits for patients who underwent
primary tumor resection. Although these were discrepant
to our result, it may be because stage IV disease included
many complicated conditions, such as the resectability of
primary tumor, the volume of metastatic tumor, the pace of
progression, and so on. To minimize the influence of these
complicated situations, only patients with stage IV disease
with a resectable primary tumor but unresectable metasta-
ses were included in the current study. For the same
purpose, we evaluated the sum of the longest diameters
of the metastases, number of metastases, and number
of organs with metastasis and confirmed that there
were no statistical differences between the two groups.
Moreover, the rapid progress made in the therapeutic
treatments for colorectal cancer should also be consid-
ered. For example, anti-epidermal growth factor receptor
(EGFR) antibodies were not included or mentioned in
most of these previous studies. While only one study has
mentioned the use of cetuximab [13,20,21], which was
added to combination therapy regimens comprising cap-
ecitabine, oxaliplatin, and bevacizumab, this regimen
was not used as standard therapy, because no survival
prolongation from adding cetuximab on bevacizumab
has been demonstrated. It is notable that an anti-EGFR
antibody was used in 73.3% of all patients who had
KRAS wild-type tumors in the current study. Moreover,
we did not observe any significant differences in the rates
in which both cytotoxic and molecular targeted agents in-
cluding anti-EGFR antibodies were used between the USC
and PTR groups. Consequently, the influences by the varied
chemotherapy regimens on the result might be minimal.
In addition to primary tumor resection, the KRAS muta-
tion was found to have a negative prognostic value in our
multivariate analysis, while a prognostic value of KRAS mu-
tation on survival in metastatic CRC is controversial in the
previous literatures [22]. KRAS mutation was not found to
affect the survival in some studies [23-26]. However, most
Table 4 Complication in PTR compared with elective






Mortality 0% 0% N.A.
Morbidity Overall 18 (42.9%) 98 (28.7%) 0.0498
>Grade 3 6 (14.3%) 38 (10.7%) 0.445
Postoperative ileus 6 (14.3%) 29 (8.2%) 0.244
Leakage 3 (7.1%) 20 (5.7%) 0.731
Surgical site infection 5 (11.9%) 32 (9.1%) 0.574
PTR: primary tumor resection group. Control: groups in which elective surgery
for stages 0 to III CRC were performed between 2010 and 2012 in our hospital.
N.A.: not available. Variables were statistically analyzed by Fisher’s exact test.
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tated KRAS compared to patients with wild-type KRAS in a
sub-analysis of a previous randomized controlled study
(RCT) with a large sample size [27]. The result of the
current study is compatible with the most recent literature.
Because the OS rates did not significantly differ be-
tween the PTR and USC groups in the present study, it
is important to evaluate the characteristics of these treat-
ments to determine which leads to a better outcome.
USC offers the possibility of avoiding potentially un-
necessary primary tumor resection, and accordingly,
the primary tumors were controlled in 80.0% of pa-
tients in the USC group in this study. However, it
should be noted that emergency laparotomy in the
USC group owing to perforation was performed in one
case (6.7%). On the other hand, 42.9% of patients in
the PTR group experienced morbidities, which is
higher than the morbidity rates observed in patients
undergoing elective surgery for stages 0 to III CRC at
our hospital (28.7% in control group, Table 4). The
high morbidity rate reported in the present study
should raise some concerns. There were no statistical
differences in each complication, such as postoperative
ileus, anastomotic leakage, and SSI, but the number in
every complication is larger in the PTR group. As the
sum, morbidity is thought to be more frequent in the PTR
group in the current study. In some previous reports
[6-9], postoperative morbidity and mortality in PTR are
reported to be higher than non-resection group such as
ostomy and bypass. However, the reason for higher mor-
bidity and mortality is still unclear. Further studies aiming
to compare directly stage IV CRC to stages 0 to III should
be required to estimate this issue in the future.
The limitation of the current study was its retrospective
nature. The small number of patients, especially in the
USC group, is also the limitation in our study. This is be-
cause the concept of USC is thought to emerge after the
appearance of molecular targeted agents that potentially
enable conversion therapies, and therefore, we have not
experienced the large number of patients yet. Althoughour result may not be conclusive, it suggests that it is im-
portant to consider the benefits and disadvantages of both
these treatments and to select an appropriate option on an
individual basis until standard therapy might be deter-
mined in the future based on the results of ongoing RCTs.
Conclusions
Our results here indicate that the OS did not differ signifi-
cantly depending on the performance of primary tumor
resection in stage IV CRC with unresectable metastases.
Furthermore, up-front systemic chemotherapy may be
valuable in avoiding unnecessary primary tumor resection
and surgical morbidity.
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